Valneva SE (VALN) EBITDA (2021 - 2026)
Valneva SE (VALN) reported EBITDA of -$21.3 million for Q1 2026, down 3276.1% on a YoY basis from $670873.2 in Q1 2025, and up 15.65% sequentially from -$25.3 million in Q4 2025.
Valneva SE (VALN) EBITDA (2021 - 2026) Analysis & Trends
Valneva SE (VALN) has 6 years of EBITDA data on file, last reported at -$21.3 million in Q1 2026.
- For the quarter ending Q1 2026, EBITDA fell 3276.1% year-over-year to -$21.3 million; the trailing twelve-month figure through Mar 2026 stood at -$89.7 million (down 104.67% YoY), and the FY2025 full-year result was -$69.1 million, down 294.18% from the prior year.
- EBITDA rose to -$21.3 million in Q1 2026, from -$25.3 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of $38.7 billion in Q4 2022 to a low of -$38.1 billion in Q3 2022.
- A 5-year average of $14.7 million and a median of -$17.4 million in 2023 frame the typical range for EBITDA.
- Peak annual rise in EBITDA reached 19080.79% in 2022, while the deepest fall reached 21259.55% in 2022.
- Tracing VALN's EBITDA over 5 years: stood at $38.7 billion in 2022, then tumbled by 100.05% to -$20.7 million in 2023, then advanced by 18.79% to -$16.8 million in 2024, then tumbled by 50.56% to -$25.3 million in 2025, then advanced by 15.65% to -$21.3 million in 2026.
- Business Quant data shows VALN's EBITDA at -$21.3 million in Q1 2026, -$25.3 million in Q4 2025, and -$37.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -15.76 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 249.90 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 394.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -445.22 Mn |
| 10 | Valneva SE | 811.46 Mn | 688.23 Mn | 5.08 Mn | -21.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -21.31 Mn |
| Dec 31, 2025 | -25.26 Mn |
| Sep 30, 2025 | -37.06 Mn |
| Jun 30, 2025 | -6.11 Mn |
| Mar 31, 2025 | -631,130.66 |
| Dec 31, 2024 | -16.78 Mn |
| Sep 30, 2024 | -8.35 Mn |
| Jun 30, 2024 | -18.09 Mn |
| Mar 31, 2024 | 79.30 Mn |
| Dec 31, 2023 | -20.66 Mn |
| Sep 30, 2023 | -19.27 Mn |
| Jun 30, 2023 | -17.42 Mn |
| Mar 31, 2023 | -13.20 Mn |
| Dec 31, 2022 | 38.67 Bn |
| Sep 30, 2022 | -38.14 Bn |
| Jun 30, 2022 | -130.93 Mn |
| Mar 31, 2022 | -14.93 Mn |
| Dec 31, 2021 | 201.58 Mn |
| Sep 30, 2021 | -178.58 Mn |
| Jun 30, 2021 | -62.38 Mn |